

Consolidated Financial Results for the Fiscal Year Ended March 31, 2013
[Japanese GAAP]

Company name: ROHTO Pharmaceutical Co., Ltd. Stock Exchange listing: TSE/OSE, First Sections
 Stock code: 4527 URL: <http://www.rohto.co.jp>
 Representative: Toshiaki Yoshino, President and COO
 Contact: Masaya Saito, Director, General Manager, Corporate Planning & Administration Department
 Telephone: 81-(0) 6-6758-1211
 Scheduled date of Annual General Meeting of Shareholders: June 21, 2013
 Scheduled date of filing of Annual Securities Report: June 24, 2013
 Scheduled date of dividend payment: June 7, 2013
 Preparation of supplementary materials for financial results: Yes
 Holding of financial results meeting: Yes (for institutional investors and analysts)

Note: The original disclosure in Japanese was released on May 15, 2013 at 15:10 (GMT +9).

(All amounts are rounded down to the nearest million yen)

1. Consolidated Financial Results for the Fiscal Year Ended March 31, 2013 (April 1, 2012 – March 31, 2013)

(1) Consolidated results of operations (Percentages for net sales and incomes represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended Mar. 31, 2013	129,146	7.4	14,380	5.5	14,730	7.6	8,087	(1.2)
Fiscal year ended Mar. 31, 2012	120,292	4.2	13,624	4.0	13,684	2.9	8,184	2.7

Note: Comprehensive income (Millions of yen): Fiscal year ended Mar. 31, 2013: 12,420 (up 65.7%)
 Fiscal year ended Mar. 31, 2012: 7,497 (up 31.8%)

	Net income per share	Diluted net income per share	ROE	Ordinary income on total assets	Operating income to net sales
	Yen	Yen	%	%	%
Fiscal year ended Mar. 31, 2013	68.78	68.49	9.2	10.3	11.1
Fiscal year ended Mar. 31, 2012	69.60	69.31	10.2	10.4	11.3

Reference: Equity in earnings of affiliates (Millions of yen): Fiscal year ended Mar. 31, 2013: (15)
 Fiscal year ended Mar. 31, 2012: (56)

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of Mar. 31, 2013	150,643	93,771	61.7	789.83
As of Mar. 31, 2012	136,008	83,627	60.9	703.93

Reference: Shareholders' equity (Millions of yen): As of Mar. 31, 2013: 92,876 As of Mar. 31, 2012: 82,773

(3) Consolidated cash flow

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year ended Mar. 31, 2013	16,702	(10,595)	(3,408)	19,867
Fiscal year ended Mar. 31, 2012	10,391	(9,605)	800	15,381

2. Dividends

	Dividend per share					Total dividends	Payout ratio (consolidated)	Dividends on equity (consolidated)
	1Q-end	2Q-end	3Q-end	Year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended Mar. 31, 2012	-	8.00	-	8.00	16.00	1,881	23.0	2.4
Fiscal year ended Mar. 31, 2013	-	8.00	-	9.00	17.00	1,999	24.7	2.3
Fiscal year ending Mar. 31, 2014 (forecast)	-	9.00	-	9.00	18.00		20.6	

3. Consolidated Forecast for the Fiscal Year Ending March 31, 2014 (April 1, 2013 – March 31, 2014)

(Percentages represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First half	64,000	8.9	5,400	(4.1)	5,600	(5.7)	3,300	(4.3)	28.06
Full year	142,000	10.0	16,000	11.3	16,300	10.7	10,300	27.4	87.59

*** Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in change in scope of consolidation): Yes

Newly added: 1 (Rohto Pharma (India) Pvt. Ltd.)

Note: Please refer to page 21 of the attachments “4. Consolidated Financial Statements, (5) Notes to Consolidated Financial Statements” for further information.

(2) Changes in accounting policies and accounting estimates, and restatements

1) Changes in accounting policies due to revisions in accounting standards, others: Yes

2) Changes in accounting policies other than 1) above: None

3) Changes in accounting estimates: Yes

4) Restatements: None

Note: Subject to “Changes in accounting policies that are difficult to distinguish from changes in accounting estimates” since the Company has revised its depreciation method from the current fiscal year. Please refer to page 21 of the attachments “4. Consolidated Financial Statements, (5) Notes to Consolidated Financial Statements” for further information.

(3) Number of outstanding shares (common stock shares)

1) Number of shares outstanding at end of period (including treasury stock):

As of Mar. 31, 2013: 117,924,768 shares As of Mar. 31, 2012: 117,919,596 shares

2) Number of shares of treasury stock at end of period:

As of Mar. 31, 2013: 333,543 shares As of Mar. 31, 2012: 330,789 shares

3) Average number of shares outstanding during the period:

Fiscal year ended Mar. 31, 2013: 117,590,931 shares Fiscal year ended Mar. 31, 2012: 117,585,981 shares

Reference: Summary of Non-consolidated Financial Results

1. Non-consolidated Financial Results for the Fiscal Year Ended March 31, 2013 (April 1, 2012 – March 31, 2013)

(1) Non-consolidated results of operations (Percentages represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended Mar. 31, 2013	82,754	6.8	11,613	5.9	12,132	5.2	5,983	7.0
Fiscal year ended Mar. 31, 2012	77,509	0.4	10,965	1.8	11,530	2.3	5,591	(18.6)

	Net income per share	Diluted net income per share
	Yen	Yen
Fiscal year ended Mar. 31, 2013	50.88	50.67
Fiscal year ended Mar. 31, 2012	47.55	47.35

(2) Non-consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of Mar. 31, 2013	115,230	85,244	73.5	720.05
As of Mar. 31, 2012	107,533	79,818	73.7	673.87

Reference: Shareholders' equity (Millions of yen): As of Mar. 31, 2013: 84,671 As of Mar. 31, 2012: 79,239

2. Non-consolidated Forecast for the Fiscal Year Ending March 31, 2014 (April 1, 2013 – March 31, 2014)

(Percentages represent year-on-year changes)

	Net sales		Ordinary income		Net income		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First half	40,000	1.7	4,900	(10.1)	3,200	0.4	27.21
Full year	83,500	0.9	12,200	0.6	7,600	27.0	64.63

Note 1: Indication of audit procedure implementation status

This summary report is not subject to the audit procedures based on the Financial Instruments and Exchange Law. At the time when this report was released, the audit procedures for financial statements have not been completed.

Note 2: Cautionary statement with respect to forward-looking statements and other special items

Forecasts regarding future performance in these materials are based on assumptions judged to be valid and information available to the Company at the time the materials were created. Actual results of operations may differ significantly from the forecasts depending on various factors. For discussion of the assumptions and other factors considered by the

Company in preparing the above projections, please refer to page 2 of the attachments “1. Analysis of Results of Operations and Financial Position, (1) Analysis of Results of Operations.”

Contents of Attachments

1. Analysis of Results of Operations and Financial Position	2
(1) Analysis of Results of Operations	2
(2) Analysis of Financial Position	5
(3) Basic Policy of Profit Distribution and Dividends for the Current and Next Fiscal Years	6
2. Corporate Group	7
3. Management Policies	9
(1) Basic Management Policy	9
(2) Target Performance Indicators	9
(3) Medium- and Long-term Business Strategy and Challenges	9
(4) Other Important Management Matters	10
4. Consolidated Financial Statements	11
(1) Consolidated Balance Sheets	11
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	13
(3) Consolidated Statements of Change in Shareholders' Equity	16
(4) Consolidated Statements of Cash Flows	19
(5) Notes to Consolidated Financial Statements	21
Going Concern Assumption	21
Significant Accounting Policies in the Preparation of Consolidated Financial Statements	21
Change in Accounting Policies	21
Segment and Other Information	22
Per-share Information	26
Material Subsequent Events	26

1. Analysis of Results of Operations and Financial Position

(1) Analysis of Results of Operations

(Millions of yen)

	Net sales	Operating income	Ordinary income	Net income
Fiscal year ended Mar. 31, 2013	129,146	14,380	14,730	8,087
Fiscal year ended Mar. 31, 2012	120,292	13,624	13,684	8,184
Year-on-year change (%)	7.4	5.5	7.6	(1.2)

This fiscal year, Japanese economy showed the first tentative signs of a recovery in consumer confidence after a change in government in December 2012 brought expectations for economic policy initiatives accompanied by a falling yen and rising stock market. Overseas, the situation generally remained harsh due to a slowdown resulting from such factors as the financial crisis in Europe and protracted deceleration in the emerging economies.

In this situation, the Rohto Group has moved into new customer-oriented product development and marketing activities. In its existing categories, the Group endeavored to develop high value-added products and activate markets.

In Japan, net sales rose on the back of strong performances from “*Alguard*” due to the higher level of pollen dispersal in the spring of 2013, and the functional cosmetics brand “*Obagi*”, which benefited from the release of new products. Overseas, sales fell on a local currency basis in Europe and the United States amid a sense of economic slowdown stemming from the European debt crisis, but rose on conversion into yen due to the yen’s depreciation. Moreover, active marketing of “*Hada-Labo*” and other products led to a sales surge in the Asian economies that have been driving growth.

In total, net sales rose 7.4% year on year to 129,146 million yen, the 20th successive year of increase.

Regarding profits, the efforts to enhance efficiency in the area of selling, general and administrative expenses combined with strong sales, operating income rose 5.5% year on year to 14,380 million yen, ordinary income rose 7.6% to 14,730 million yen and net income fell 1.2% to 8,087 million yen due to the booking of an extraordinary loss on investment securities based on the valuations.

The sales summary by reportable segment is as follows.

(Millions of yen)

		Net sales (Sales to customers)			
		Fiscal year ended Mar. 31, 2012	Fiscal year ended Mar. 31, 2013	Year-on-year change (Amount)	Year-on-year change (%)
Reportable segment	Japan	85,387	89,641	4,254	5.0
	America	5,574	5,619	45	0.8
	Europe	3,914	3,962	47	1.2
	Asia	24,014	28,179	4,165	17.3
	Subtotal	118,890	127,403	8,513	7.2
Others	1,402	1,742	340	24.3	
Total		120,292	129,146	8,853	7.4

Japan

Sales to customers reached 89,641 million yen, a year-on-year rise amounting to 5.0%.

The outlook for the healthcare market in Japan remained harsh due to such factors as intensifying competition with the entry of cross-industry newcomers. Moreover, this business environment continues, with overall market sales underperforming those for the previous year.

In this situation, Rohto has undertaken to sell new products in response to changing consumer needs and aggressively strengthened marketing activities.

Sales of the “*Alguard*” brand broke all records due to the higher level of pollen dispersal in this spring and the launch of new products. The “*Obagi*” brand, especially new products such as “*Obagi Derma Elastic X*” lift care series combining original ingredients, also performed well, as did sunscreens developed to offer the highest class of PA value according to the new PA rating standards. The “*Senobic*” beverage to support nutrition during children’s growth phases, limited to direct mail order, sold strongly. Finally, the advance to full-scale operation of Shizuoka No. 2 Plant at the subsidiary Meguro Kako was accompanied by rising sales.

Meanwhile, sales of the “*Hada-Labo*” series declined after being the subject of a Disney campaign in the previous fiscal year, but a major renewal in March 2013 fed through to the market and led to strong sales. Segment profits increased 3.0% year on year to 10,697 million yen due to strong sales.

America

Sales to customers rose 0.8 % year on year to 5,619 million yen.

The U.S. economy is recovering little by little due to an improved employment situation and the steady change of the individual consumption.

The eye care category, focused on “*Rohto Cool*” eye drops, performed well, while in the skincare category sales fell for leading products “*Soft Lips*.”

Segment profits fell 17.6% year on year to 454 million yen due to falls on a local currency basis, despite the effective use of expenses.

Europe

Sales to customers rose 1.2% year on year to 3,962 million yen.

Despite an inevitable fall in sales on a local currency basis amid the delayed recovery from the impact of the European financial crisis, sales rose after currency conversion into yen.

Segment profits increased 125.5% year on year to 371 million yen due to effective use of the advertising and sales promotion expenses.

Asia

Sales to customers rose 17.3% year on year to 28,179 million yen.

Skincare products such as “*Hada-Labo*”, “*Mentholatum Men*” cosmetics, and “*Sunplay*” sunscreen, which are being aggressively marketed in Asia (especially China), performed well. Regarding “*Hada-Labo*,” sales soared with the release of new products after the Chinese sales environment slowly normalized following a temporary dip and contributed to the rise in sales.

Segment profits rose 12.7% year on year to 2,595 million yen, despite the cost of investment to cultivate business

in emerging nations.

Others

In “Others”, excluded from reportable segments, sales to customers increased 24.3% year on year to 1,742 million yen.

Segment profits rose 29.7% year on year to 109 million yen.

Reference: Sales by product and service segment

Sales by product and service segment are as follows.

(Millions of yen)

	Net sales			
	Fiscal year ended Mar. 31, 2012	Fiscal year ended Mar. 31, 2013	Year-on-year change (Amount)	Year-on-year change (%)
Eye care	25,308	27,251	1,942	7.7
Skincare	73,777	81,168	7,390	10.0
Internal medicines and food	16,512	16,350	(161)	(1.0)
Others	4,694	4,376	(317)	(6.8)
Total	120,292	129,146	8,853	7.4

Outlook for the fiscal year ending March 31, 2014

(Millions of yen)

	Net sales	Operating income	Ordinary income	Net income
Fiscal year ending Mar. 31, 2014	142,000	16,000	16,300	10,300
Fiscal year ended Mar. 31, 2013	129,146	14,380	14,730	8,087
Year-on-year change (%)	10.0	11.3	10.7	27.4

Net sales, operating income and ordinary income performed strongly in the current fiscal year, reaching record levels amid a harsh environment. Looking to the future, although the Japanese economy is predicted to recover gradually due to anticipated economic initiatives accompanied by a falling yen and rising stock market, the competition in the healthcare market should also heat up with the entry of cross-industry newcomers.

Under such conditions, the Rohto Group will adapt to the changes in the business environment, aiming to expand business further and improve earnings by creating new products and brands that respond appropriately to changing customer needs. The Group is also taking on the challenge of a range of innovations including entering new businesses domains.

In Japan segment, we anticipated that competition would continue to be intensified, and are focusing on the beauty category as well as developing new products and improving our existing brands. In addition, we aim to increase sales through the full-scale operation and increase the number of manufacture on assignment at Shizuoka No. 2 Plant at Meguro Kako, and the expansion of direct mail orders. Overseas, we anticipate rising sales from growth in Asia, led by China and supported by Vietnam, Indonesia, Malaysia, and other ASEAN nations.

In the next fiscal year we anticipate that net sales will rise 10.0% year on year to 142.0 billion yen, operating income 11.3% to 16.0 billion yen, ordinary income 10.7% to 16.3 billion yen, and net income 27.4% to 10.3 billion yen. Furthermore, we expect net sales to rise for 21st consecutive fiscal year, and to set a new profit record.

These forecasts are based on an exchange rate of 95 yen to the US dollar.

(2) Analysis of Financial Position**Balance sheet and cash flow position**

Balance sheet position

Total assets at the end of the current fiscal year rose 14,634 million yen from the end of the previous fiscal year to 150,643 million yen. This was mainly due to the factors that include rises of 4,487 million yen in cash and deposits, 3,592 million yen in investment securities, 3,039 million yen in long-term loans receivable and 2,129 million yen in property, plant and equipment.

Total liabilities rose 4,490 million yen from the end of the previous fiscal year to 56,871 million yen. This was due to such factors as a fall of 1,756 million yen in long-term loans payable set against rises of 3,104 million yen in accrued expense, 1,347 million yen in deferred tax liabilities (non-current liabilities), 508 million yen in short-term loans payable, and 480 million yen in reserve for returned goods unsold.

Net assets rose 10,144 million yen from the end of the previous fiscal year to 93,771 million yen, due to such factors as rises of 5,863 million yen in retained earnings, 2,893 million yen in translation adjustments and 1,457 million yen in valuation difference on available-for-sale securities.

Cash flow position

(Millions of yen)

Item	Fiscal year ended Mar. 31, 2012	Fiscal year ended Mar. 31, 2013	Year-on-year change (Amount)
Cash and cash equivalents at beginning of year	14,005	15,381	1,375
Cash flows from operating activities	10,391	16,702	6,311
Cash flows from investing activities	(9,605)	(10,595)	(990)
Cash flows from financing activities	800	(3,408)	(4,208)
Effect of exchange rate changes on cash and cash equivalents	(210)	1,742	1,953
Increase (decrease) in cash and cash equivalents	1,375	4,441	3,065
Increase in cash and cash equivalents from newly consolidated subsidiary	-	45	45
Cash and cash equivalents at end of period	15,381	19,867	4,486

During the current fiscal year, there was a net increase of 4,486 million yen in cash and cash equivalents to 19,867 million yen.

Operating activities

Net cash provided by operating activities rose 6,311 million yen year on year to 16,702 million yen. This was mainly attributable to income before income taxes and minority interests of 13,630 million yen, depreciation and amortization of 5,256 million yen, a 1,432 million yen decrease in notes and accounts receivable-trade, and income taxes paid of 5,306 million yen.

Investing activities

Net cash used in investing activities rose 990 million yen year on year to 10,595 million yen. This was mainly attributable to purchase of property, plant and equipment of 5,130 million yen, payments of long-term loans receivable of 2,483 million yen, and purchase of investment securities of 2,449 million yen.

Financing activities

Net cash used in financing activities rose 4,208 million yen year on year to 3,408 million yen, compared with 800 million yen provided a year earlier. This was due to the repayment of long-term loans payable of 2,292 million yen, cash dividends paid of 1,881 million yen and net increase in short-term loans

payable of 804 million yen.

Reference: Trends in cash flow indicators

	75th Fiscal year ended Mar. 31, 2011	76th Fiscal year ended Mar. 31, 2012	77th Fiscal year ended Mar. 31, 2013
Shareholders' equity ratio (%)	60.9	60.9	61.7
Shareholders' equity ratio based on market price (%)	82.8	89.3	100.5
Interest-bearing debt to cash flow ratio	0.5	0.7	0.4
Interest coverage ratio	50.0	74.1	118.7

* Shareholders' equity ratio = Shareholders' equity / Total assets

Shareholders' equity ratio based on market price = Market capitalization / Total assets

Interest-bearing debt to cash flow ratio = Interest-bearing debt / Operating cash flows (before interests and income taxes paid)

Interest coverage ratio = Operating cash flows (before interests and income taxes paid) / Interest payments

1. All indices are calculated based on consolidated figures.

2. Market capitalization: Closing stock price on the balance sheet date x number of shares outstanding (net of treasury stock shares) on the balance sheet date

3. Operating cash flows (before interests and income taxes paid) are calculated using the figures for cash flows from operating activities (before interests and income taxes paid) in the consolidated statements of cash flows. Interest-bearing debt includes all liabilities on the consolidated balance sheets that incur interest. Interest payments are calculated using the figures for interest expenses paid in the consolidated statements of cash flows.

(3) Basic Policy of Profit Distribution and Dividends for the Current and Next Fiscal Years

Constantly and consistently returning to shareholders the profits earned through business activities is one of our highest priorities. The fundamental policy is to pay a dividend based on operating results. Retained earnings will be used effectively for the development of new products, the investments in manufacturing equipment, and others to respond to changes in the operating environment. We believe that these investments will contribute to future earnings, thereby enabling the Company to pay a large and stable dividend to shareholders.

We plan to distribute a year-end dividend of 9 yen per share for the current fiscal year. Added to the interim dividend of 8 yen, which has been already distributed, this will bring the annual dividend to a total of 17 yen per share.

For the next fiscal year, with our gratitude to all the shareholders who support us on a regular basis, we plan to pay 9 yen per share as interim and year-end dividends to bring the annual total to 18 yen per share.

2. Corporate Group

The Rohto Group comprises ROHTO Pharmaceutical Co., Ltd. (“the Company”), 36 subsidiaries and 6 affiliates. These companies are engaged primarily in the manufacture and sale of eye care products (including eye drops and eyewash preparations), skincare products (including dermal medicines, lip balm, sunscreen, and functional cosmetics), internal medicines and food products (including gastrointestinal medicines, traditional Chinese herbal medicines, and supplements), and other products (including in-vitro test kits) in the health and beauty care domains.

The positioning and segmentation of the Rohto Group companies is as follows:

Japan: Rohto manufactures and sells eye care products, skincare products, internal, and food products, and other products and services. Meguro Kako Inc. mainly manufactures by contract and sells internal and foodstuff products and services.

America: The Mentholatum Company Inc. mainly manufactures and sells skincare products and services.

Europe: The Mentholatum Company Limited. mainly manufactures and sells skincare products and services.

Asia: The Mentholatum (Asia Pacific) Ltd., Mentholatum (China) Pharmaceutical Co., Ltd., and other local subsidiaries mainly manufacture and sell eye care and skincare products and services.


	Number of subsidiaries and affiliates	Major subsidiaries and affiliates
Japan	The Company Consolidated subsidiaries: 6 Non-consolidated subsidiaries not accounted for under the equity method: 5 Equity-method affiliate: 1	Manufacture/sale Meguro Kako Inc. *1 Ands Corporation *2 Sale Medicare Systems Co., Ltd. *1, *3
America	Consolidated subsidiaries: 5 Non-consolidated subsidiary not accounted for under the equity method: 1 Equity-method affiliate: 1 Affiliates not accounted for under the equity method: 2	Manufacture/sale The Mentholatum Company Inc. *1 Investment management Rohto USA, Inc. *1
Europe	Consolidated subsidiaries: 5	Manufacture/sale The Mentholatum Company Limited *1
Asia	Consolidated subsidiaries: 10 Non-consolidated subsidiary accounted for under the equity method: 1 Non-consolidated subsidiaries not accounted for under the equity method: 2 Affiliates not accounted for under the equity method: 2	Manufacture/sale Mentholatum (China) Pharmaceutical Co., Ltd. *1 Rohto-Mentholatum (Vietnam) Co., Ltd. *1 PT Rohto Laboratories Indonesia *1 Tianjin ROHTO Herbal Medicine Co., Ltd. *1 Sale Mentholatum (Asia Pacific) Ltd. *1 Mentholatum Taiwan Ltd. *1 Episteme Trading (Shanghai) Co., LTD. *1 Rohto Pharma (India) Pvt. Ltd. *1
Other	Consolidated subsidiary: 1	Manufacture/sale Mentholatum Australasia Pty. Ltd. *1

*1. Consolidated subsidiaries

*2. Equity-method affiliates

*3. Medicare Systems Co., Ltd. dissolved in the current fiscal year. This company is currently being liquidated.

Business structures of Rohto is shown below.



3. Management Policies

(1) Basic Management Policy

The Rohto Group aims to help individuals age gracefully in accordance with its corporate slogan that pledges to bring “Happy Surprises.” Since the establishment of Rohto, we have focused on creating a broad range of healthcare products, including eye drops, gastrointestinal medicines, and dermal medication, and developing new markets with the spirit of persistence and taking on new challenges. Even in times of upheaval we will remain committed to the spirit of this slogan as we aim to become a constant source of surprise and happiness for customers and society at large.

At the same time, the Rohto Group is dedicated to earning the trust and meeting the expectations of shareholders, customers, business partners, employees, society and all other stakeholders while operating in a manner that promotes mutual prosperity with others.

(2) Target Performance Indicators

Our primary goals are maximizing shareholder value and enhancing the satisfaction of all stakeholders. In the healthcare market, our objective is to establish brands that are either number one or among the leaders in their respective categories. In addition, management places priority on earnings indicators, particularly the operating margin, return on equity and ordinary income on total assets.

(3) Medium- and Long-term Business Strategy and Challenges

People are growing more health-conscious as the population ages, and are looking beyond the functions of medication to focus on staying youthful and leading long, healthy lives. Accordingly, the healthcare market is growing increasingly important. Meanwhile consumer spending remains sluggish in the harsh economic environment, and consumers are tightening their belts in the wake of the Great Earthquake.

In response, we are seeking “innovative items” that consumers demand, beyond the pharmaceuticals category. We are targeting the broad “health and beauty” field. By developing value-added products and creating brands that meet new needs, we aim to establish brands that rank either first or among the leaders in their respective markets.

To adapt to the significant changes now taking place in the operating environment, we believe that superiority in product development and technologies is vital in order to earn the trust of customers and become more competitive. Rohto Research Village Kyoto is the R&D base for these activities. The facility strengthens the technological foundation for healthcare operations. This research village is also the center for actions involving antiaging and the disease prevention, collaboration with venture capital-backed companies and joint research projects with partners in Japan and overseas. We are determined to rapidly build a broad-based research infrastructure that covers the entire health and beauty domain.

Rohto is accelerating global operations development to deliver our products all over the world. In Asian region, especially China and Vietnam, we will strengthen our inter-company networks, including Japan, and we will exploit the advantages developed from an early stage in the Asian region to achieve further growth. Moreover, we will aggressively explore opportunities in next emerging countries with growth prospects. We will also develop our operational group synergy in America and Europe.

Furthermore, we plan to expand our business domains into the fields of regenerative medicine and food in order to contribute more profoundly to well-being as we enlarge the boundaries of the traditional “health and beauty” field.

We are also fulfilling our social responsibilities, in addition to the development of business activities. In 2011, we established a new division, post-disaster reconstruction support office (currently, the reconstruction support office) to provide help over the mid- to long-term.

In order to carry out the “next-generation support” activities that comprise our CSR theme, we are supporting orphaned children in the earthquake in the aspect of their lives and academic achievements over the long-term period.

(4) Other Important Management Matters

No reportable information.

4. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

	FY3/12 (As of Mar. 31, 2012)	FY3/13 (As of Mar. 31, 2013)
Assets		
Current assets		
Cash and deposits	15,381	19,868
Notes and accounts receivable-trade	31,898	31,896
Merchandise and finished goods	10,913	11,397
Work in process	1,161	1,480
Raw materials and supplies	5,931	6,579
Deferred tax assets	3,539	4,069
Other	2,549	2,231
Allowance for doubtful accounts	(94)	(56)
Total current assets	71,280	77,467
Fixed assets		
Property, plant and equipment		
Buildings and structures	36,199	38,690
Accumulated depreciation	(17,176)	(18,724)
Buildings and structures, net	19,022	19,965
Machinery, equipment and vehicles	35,860	39,843
Accumulated depreciation	(26,518)	(29,454)
Machinery, equipment and vehicles, net	9,342	10,389
Equipment	8,946	9,653
Accumulated depreciation	(7,758)	(8,065)
Equipment, net	1,187	1,587
Land	10,217	10,613
Construction in progress	2,782	2,097
Other	95	133
Accumulated depreciation	(20)	(30)
Other, net	75	103
Total property, plant and equipment	42,628	44,758
Intangible fixed assets		
Goodwill	958	766
Other	1,315	1,241
Total intangible fixed assets	2,273	2,008
Investments and other assets		
Investment securities	14,945	18,537
Long-term loans receivable	352	3,392
Deferred tax assets	2,452	2,697
Other	2,204	2,451
Allowance for doubtful accounts	(128)	(670)
Total investments and other assets	19,826	26,408
Total fixed assets	64,727	73,175
Total assets	136,008	150,643

	(Millions of yen)	
	FY3/12 (As of Mar. 31, 2012)	FY3/13 (As of Mar. 31, 2013)
Liabilities		
Current liabilities		
Notes and accounts payable-trade	10,525	10,151
Short-term loans payable	5,103	5,611
Accrued expenses	16,029	19,133
Accrued income taxes	2,755	2,914
Accrued consumption tax	294	527
Deferred tax liabilities	252	328
Reserve for bonuses	1,861	1,979
Reserve for directors' bonuses	30	30
Reserve for returned goods unsold	700	1,180
Reserve for rebates of sales	2,651	2,760
Other	4,731	4,937
Total current liabilities	44,935	49,554
Non-current liabilities		
Long-term loans payable	3,335	1,578
Deferred tax liabilities	1,917	3,264
Reserve for retirement benefits	1,843	2,013
Reserve for directors' retirement benefits	69	80
Other	279	379
Total non-current liabilities	7,445	7,316
Total liabilities	52,380	56,871
Net assets		
Shareholders' equity		
Capital stock	6,405	6,408
Capital surplus	5,524	5,527
Retained earnings	73,814	79,677
Treasury stock	(270)	(273)
Total shareholders' equity	85,475	91,341
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	3,013	4,471
Translation adjustments	(5,133)	(2,239)
Adjustments to foreign subsidiaries' pension liabilities	(581)	(695)
Total accumulated other comprehensive income	(2,701)	1,535
Stock acquisition rights	579	573
Minority interests	273	320
Total net assets	83,627	93,771
Total liabilities and net assets	136,008	150,643

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income**Consolidated Statements of Income**

(Millions of yen)

	FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)	FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)
Net sales	120,292	129,146
Cost of sales	49,928	52,792
Gross profit	70,363	76,353
Provision of reserve for returned goods unsold	-	480
Reversal of reserve for returned goods unsold	131	-
Gross profit -net	70,495	75,873
Selling, general and administrative expenses		
Promotion expenses	14,680	15,794
Advertising expenses	18,228	19,437
Salaries and bonuses	7,039	7,715
Provision of reserve for bonuses	866	937
Provision of reserve for directors' bonuses	30	30
Retirement benefit expenses	428	568
Provision of reserve for directors' retirement benefits	11	11
Depreciation and amortization	781	733
Amortization of goodwill	246	192
R&D expenses	3,717	4,062
Other	10,842	12,010
Total selling, general and administrative expenses	56,871	61,493
Operating income	13,624	14,380
Non-operating income		
Interest income	96	129
Dividend income	378	354
Other	163	330
Total non-operating income	638	814
Non-operating expenses		
Interest expenses	223	180
Equity in losses of affiliates	56	15
Loss on retirement of fixed assets	29	99
Other	269	169
Total non-operating expenses	578	464
Ordinary income	13,684	14,730
Extraordinary income		
Gain on sales of investment securities	202	-
Patent royalty revenue	281	-
State subsidies	-	319
Total extraordinary income	484	319

(Millions of yen)

	FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)	FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)
Extraordinary losses		
Loss on valuation of investment securities	-	644
Loss on valuation of stocks of subsidiaries and affiliates	45	-
Loss on valuation of other investment	-	212
Provision of allowance for doubtful accounts	-	530
Provision of allowance for doubtful account for subsidiaries and affiliates	35	33
Total extraordinary losses	80	1,420
Income before income taxes and minority interests	14,088	13,630
Current income taxes	5,667	5,586
Deferred income taxes	276	(57)
Total income taxes	5,944	5,528
Income before minority interests	8,144	8,101
Minority interests in income (loss)	(39)	14
Net income	8,184	8,087

Consolidated Statements of Comprehensive Income

(Millions of yen)

	FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)	FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)
Income before minority interests	8,144	8,101
Other comprehensive income		
Valuation difference on available-for-sale securities	(167)	1,453
Translation adjustments	(209)	2,975
Adjustments to foreign subsidiaries' pension liabilities	(272)	(113)
Share of other comprehensive income of associates accounted for using equity method	2	3
Total other comprehensive income	(646)	4,318
Comprehensive income	7,497	12,420
Comprehensive income attributable to		
Comprehensive income attributable to owners of the parent	7,566	12,374
Comprehensive income attributable to minority interests	(68)	45

(3) Consolidated Statements of Change in Shareholders' Equity

(Millions of yen)

	FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)	FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)
Shareholders' equity		
Capital stock		
Balance at the beginning of current period	6,398	6,405
Changes of items during the period		
Issuance of new shares	7	3
Total changes of items during the period	7	3
Balance at the end of current period	6,405	6,408
Capital surplus		
Balance at the beginning of current period	5,517	5,524
Changes of items during the period		
Issuance of new shares	6	2
Total changes of items during the period	6	2
Balance at the end of current period	5,524	5,527
Retained earnings		
Balance at the beginning of current period	67,511	73,814
Changes of items during the period		
Dividends from surplus	(1,881)	(1,881)
Net income	8,184	8,087
Change in scope of consolidation	-	(342)
Total changes of items during the period	6,302	5,863
Balance at the end of current period	73,814	79,677
Treasury stock		
Balance at the beginning of current period	(268)	(270)
Changes of items during the period		
Purchase of treasury stock	(1)	(2)
Total changes of items during the period	(1)	(2)
Balance at the end of current period	(270)	(273)
Total shareholders' equity		
Balance at the beginning of current period	79,159	85,475
Changes of items during the period		
Issuance of new shares	14	6
Dividends from surplus	(1,881)	(1,881)
Net income	8,184	8,087
Purchase of treasury stock	(1)	(2)
Change in scope of consolidation	-	(342)
Total changes of items during the period	6,315	5,866
Balance at the end of current period	85,475	91,341

(Millions of yen)

	FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)	FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities		
Balance at the beginning of current period	3,179	3,013
Changes of items during the period		
Net changes of items other than shareholders' equity	(165)	1,457
Total changes of items during the period	(165)	1,457
Balance at the end of current period	3,013	4,471
Translation adjustments		
Balance at the beginning of current period	(4,953)	(5,133)
Changes of items during the period		
Net changes of items other than shareholders' equity	(179)	2,893
Total changes of items during the period	(179)	2,893
Balance at the end of current period	(5,133)	(2,239)
Adjustments to foreign subsidiaries' pension liabilities		
Balance at the beginning of current period	(309)	(581)
Changes of items during the period		
Net changes of items other than shareholders' equity	(272)	(113)
Total changes of items during the period	(272)	(113)
Balance at the end of current period	(581)	(695)
Total accumulated other comprehensive income		
Balance at the beginning of current period	(2,083)	(2,701)
Changes of items during the period		
Net changes of items other than shareholders' equity	(617)	4,236
Total changes of items during the period	(617)	4,236
Balance at the end of current period	(2,701)	1,535
Stock acquisition rights		
Balance at the beginning of current period	593	579
Changes of items during the period		
Net changes of items other than shareholders' equity	(13)	(5)
Total changes of items during the period	(13)	(5)
Balance at the end of current period	579	573
Minority interests		
Balance at the beginning of current period	241	273
Changes of items during the period		
Net changes of items other than shareholders' equity	32	47
Total changes of items during the period	32	47
Balance at the end of current period	273	320

	(Millions of yen)	
	FY3/12	FY3/13
	(Apr. 1, 2011 – Mar. 31, 2012)	(Apr. 1, 2012 – Mar. 31, 2013)
Total net assets		
Balance at the beginning of current period	77,911	83,627
Changes of items during the period		
Issuance of new shares	14	6
Dividends from surplus	(1,881)	(1,881)
Net income	8,184	8,087
Purchase of treasury stock	(1)	(2)
Change in scope of consolidation	-	(342)
Net changes of items other than shareholders' equity	(599)	4,278
Total changes of items during the period	5,715	10,144
Balance at the end of current period	83,627	93,771

(4) Consolidated Statements of Cash Flows

	(Millions of yen)	
	FY3/12	FY3/13
	(Apr. 1, 2011 – Mar. 31, 2012)	(Apr. 1, 2012 – Mar. 31, 2013)
Cash flows from operating activities		
Income before income taxes and minority interests	14,088	13,630
Depreciation and amortization	4,890	5,256
Amortization of goodwill	246	192
Increase (decrease) in allowance for doubtful accounts	(20)	(27)
Increase (decrease) in reserve for bonuses	(21)	115
Increase (decrease) in reserve for directors' bonuses	5	-
Increase (decrease) in reserve for retirement benefits	436	30
Increase (decrease) in reserve for returned goods unsold	(131)	480
Increase (decrease) in reserve for rebates of sales	214	109
Provision of allowance for doubtful account	-	530
Provision of allowance for doubtful account for subsidiaries and affiliates	35	33
Loss (gain) on sales of investment securities	(202)	-
Loss (gain) on valuation of investment securities	1	644
Loss on valuation of stocks of subsidiaries and affiliates	45	-
Loss on valuation of other long-term investment	-	212
Interest and dividend income	(474)	(484)
Interest expenses	223	180
Equity in (earnings) losses of affiliates	56	15
Decrease (increase) in notes and accounts receivable-trade	(1,968)	1,432
Decrease (increase) in inventories	(1,799)	(656)
Increase (decrease) in notes and accounts payable-trade	1,378	(884)
Other	(506)	937
Subtotal	16,494	21,748
Interest and dividends income received	438	447
Interest expenses paid	(228)	(187)
Income tax paid	(6,314)	(5,306)
Net cash provided by operating activities	10,391	16,702
Cash flows from investing activities		
Purchase of property, plant and equipment	(8,276)	(5,130)
Purchase of intangible fixed assets	(406)	(273)
Purchase of investment securities	(1,049)	(2,449)
Proceeds from sales of investment securities	833	-
Decrease (increase) in short-term loans receivable	(390)	(259)
Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation	-	96
Proceeds from state subsidies received	31	319
Payments of long-term loans receivable	(221)	(2,483)
Other	(126)	(414)
Net cash used in investing activities	(9,605)	(10,595)

	(Millions of yen)	
	FY3/12	FY3/13
	(Apr. 1, 2011 – Mar. 31, 2012)	(Apr. 1, 2012 – Mar. 31, 2013)
Cash flows from financing activities		
Net increase (decrease) in short-term loans payable	376	804
Proceeds from long-term loans payable	3,354	
Repayment of long-term loans payable	(1,122)	(2,292)
Cash dividends paid	(1,881)	(1,881)
Other	74	(38)
Net cash provided by (used in) financing activities	800	(3,408)
Effect of exchange rate changes on cash and cash equivalents	(210)	1,742
Increase (decrease) in cash and cash equivalents	1,375	4,441
Cash and cash equivalents at the beginning of period	14,005	15,381
Increase in cash and cash equivalents from newly consolidated subsidiary	-	45
Cash and cash equivalents at the end of period	15,381	19,867

(5) Notes to Consolidated Financial Statements**Going Concern Assumption**

No reportable information.

Significant Accounting Policies in the Preparation of Consolidated Financial Statements

1. Scope of consolidation

(1) Number of consolidated subsidiaries: 27

Name of major consolidated subsidiaries:

Rohto USA, Inc., The Mentholatum Company Inc., The Mentholatum Company Limited, Mentholatum (Asia Pacific) Ltd., Mentholatum (China) Pharmaceutical Co., Ltd., Mentholatum Taiwan Ltd., PT Rohto Laboratories Indonesia, Rohto-Mentholatum (Vietnam) Co., Ltd., Medicare Systems Co., Ltd., Meguro Kako Inc., Episteme Trading (Shanghai) Co., LTD., Tianjin ROHTO Herbal Medicine Co., Ltd., Rohto Pharma (India) Pvt. Ltd.

Effective from the current fiscal year, Rohto Pharma (India) Pvt. Ltd., non-consolidated subsidiary in the previous fiscal year, has been included in the consolidation because of its increased materiality of impact on consolidated financial statements. Ran no Sato Okinawa Co., Ltd. has been included in the consolidation since it became a consolidated subsidiary in the current fiscal year.

Medicare Systems Co., Ltd. dissolved in the current fiscal year. This company is currently being liquidated.

(2) Major non-consolidated subsidiaries

PT Rohto Farma Indonesia and Rohto Pia Co., Ltd.

Rohto Pia Co., Ltd. was renamed from Yamato Kaihatsu Kogyo on February 22, 2013.

Reason for exclusion

These subsidiaries are not included in the scope of consolidation since each of them is a small-scale business whose total assets, net sales, net income/loss (equity in earnings) and retained earnings (equity in earnings) have no significant effect on the overall results of consolidated financial statements.

2. Application of the equity method

(1) Number of non-consolidated subsidiaries accounted for under the equity method: 1

Major company: PT Rohto Farma Indonesia

(2) Number of equity-method affiliates: 2

Major company: Ands Corporation

(3) The non-consolidated subsidiaries (Rohto Pia Co., Ltd.) and affiliates (Nagai (Vietnam) Co., Ltd., etc.) are not accounted for under the equity method since they have a very minor effect on net income/loss (equity in earnings) and retained earnings (equity in earnings), and are relatively insignificant in the context of the consolidated financial statements.

Change in Accounting Policies

Changes in accounting policies that are difficult to distinguish from changes in accounting estimates

Following tax law revisions, from the current fiscal year, the Company and its domestic consolidated subsidiaries have changed its method of depreciation of property, plant and equipment acquired on or after April 1, 2012 in line with methods prescribed in the revised Corporation Tax Law.

The effect of this change on operating income, ordinary income and income before income taxes and

minority interests in the current fiscal year is insignificant.

Segment and Other Information

Segment Information

1. Overview of reportable segments

Segments used for financial reporting are the Company's constituent units for which separate financial information is available and for which the Board of Directors performs periodic studies for the purposes of determining the allocation of resources and evaluating performance.

The Company undertakes production and sales activities mainly in the health and beauty care categories. Within Japan, these operations are mainly handled by the Company. Overseas, operations are mainly handled by The Mentholatum Company, Inc. in America, The Mentholatum Company Limited. in Europe, and The Mentholatum (Asia Pacific) Ltd. and Mentholatum (China) Pharmaceutical Co., Ltd. in Asia, together with overseas affiliates. These affiliates each operate as autonomous business units, formulating comprehensive strategies in each region and developing business activities for the products and services they undertake.

Accordingly, the Company comprises the four geographical reportable segments of Japan, America, Europe, and Asia based on our production and sales structure. Each segment produces and sells eye care (including eye drops and eyewash preparations), skincare (including dermal medicines, lip balm, sunscreens, and functional cosmetics, etc.), internal medicines and food (including gastrointestinal medicines, traditional Chinese herbal medicines and supplements), and other products and services, such as in-vitro test kits.

2. Calculation methods for net sales, profits/losses, assets, liabilities, and other items for each reportable segment

The accounting treatment methods for reportable segments are generally the same as those listed in "Significant Accounting Policies in the Preparation of Consolidated Financial Statements" presented in the Group's annual securities report (Yuka Shoken Hokokusho.)

Profits for reportable segments are generally operating income figures. Inter-segment sales and transfers are determined based on market prices.

3. Information related to net sales, profit/loss, assets, liabilities, and other items for each reportable segment

FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)

(Millions of yen)

	Reportable segment					Others (Note 2)	Total	Adjustment (Note 3)	Amounts shown on consolidated financial statements (Note 4)
	Japan	America	Europe	Asia	Subtotal				
Net sales									
(1) Sales to customers	85,387	5,574	3,914	24,014	118,890	1,402	120,292	-	120,292
(2) Inter-segment sales and transfers	1,433	1,183	2	1,523	4,142	17	4,159	(4,159)	-
Total	86,820	6,757	3,916	25,537	123,033	1,419	124,452	(4,159)	120,292
Segment profit	10,384	550	164	2,302	13,402	84	13,486	137	13,624
Segment assets	117,333	9,052	3,017	26,587	155,990	979	156,970	(20,961)	136,008
Segment liabilities	36,528	4,075	1,183	11,377	53,165	285	53,450	(1,069)	52,380
Other items									
Depreciation	4,019	193	95	421	4,729	15	4,744	-	4,744
Amortization of goodwill	191	54	-	-	246	-	246	-	246
Increase in property, plant and equipment and intangible fixed assets	6,351	237	29	1,776	8,395	17	8,412	-	8,412

Notes: 1. "America" includes the business activities of overseas entities in the U.S. and Canada; "Europe" those in the U.K. and South Africa; and "Asia" those in China, Taiwan, Vietnam, and others.

2. "Others" is businesses that is excluded in reportable segments, and includes the business activities of an entity in Australia.

3. (1) "Adjustment" (137 million yen) to segment profit indicates elimination for intersegment transactions.

(2) "Adjustment" to segment assets (-20,961 million yen) and liabilities (-1,069 million yen) indicate an elimination for intersegment transactions.

4. Segment profit is adjusted to be consistent with operating income shown on the consolidated statements of income.

FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)

(Millions of yen)

	Reportable segment					Others (Note 2)	Total	Adjustment (Note 3)	Amounts shown on consolidated financial statements (Note 4)
	Japan	America	Europe	Asia	Subtotal				
Net sales									
(1) Sales to customers	89,641	5,619	3,962	28,179	127,403	1,742	129,146	-	129,146
(2) Inter-segment sales and transfers	1,354	1,146	2	2,325	4,828	16	4,845	(4,845)	-
Total	90,995	6,766	3,964	30,505	132,232	1,759	133,991	(4,845)	129,146
Segment profit	10,697	454	371	2,595	14,118	109	14,227	152	14,380
Segment assets	123,232	20,094	3,394	38,654	185,376	1,155	186,532	(35,889)	150,643
Segment liabilities	38,071	4,945	1,125	16,890	61,033	409	61,442	(4,571)	56,871
Other items									
Depreciation	4,249	168	101	545	5,064	16	5,080	-	5,080
Amortization of goodwill	191	-	-	0	192	-	192	-	192
Increase in property, plant and equipment and intangible fixed assets	3,860	97	25	1,976	5,960	47	6,007	-	6,007

Notes: 1. "America" includes the business activities of overseas entities in the U.S. and Canada; "Europe" those in the U.K. and South Africa; and "Asia" those in China, Taiwan, Vietnam, and others.

2. "Others" is businesses that is excluded in reportable segments, and includes the business activities of an entity in Australia.

3. (1) "Adjustment" (152 million yen) to segment profit indicates elimination for intersegment transactions.

(2) "Adjustment" to segment assets (-35,889 million yen) and liabilities (-4,571 million yen) indicate an elimination for intersegment transactions.

4. Segment profit is adjusted to be consistent with operating income shown on the consolidated statements of income.

Related information

FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)

1. Products and services information:

(Millions of yen)

	Eye care products	Skincare products	Internal medicines and food	Others	Total
Sales to customers	25,308	73,777	16,512	4,694	120,292

2. Geographical areas information

(1) Net sales

(Millions of yen)

Japan	China	Other	Total
85,337	14,662	20,292	120,292

Notes: Classification of net sales is based on the locations of the clients.

(2) Property, plant and equipment

(Millions of yen)

Japan	Other	Total
34,834	7,793	42,628

3. Major customers information

(Millions of yen)

Name	Net sales	Segment
OHKI Co., Ltd.	29,086	Japan
Alfresa Healthcare Corporation	15,175	Japan
Paltac Corporation	14,418	Japan

FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)

1. Products and services information:

(Millions of yen)

	Eye care products	Skincare products	Internal medicines and food	Others	Total
Sales to customers	27,251	81,168	16,350	4,376	129,146

2. Geographical areas information

(1) Net sales

(Millions of yen)

Japan	China	Other	Total
89,349	17,642	22,154	129,146

Notes: Classification of net sales is based on the locations of the clients.

(2) Property, plant and equipment

(Millions of yen)

Japan	China	Other	Total
34,555	4,602	5,600	44,758

3. Major customers information

(Millions of yen)

Name	Net sales	Segment
OHKI Co., Ltd.	30,783	Japan
Alfresa Healthcare Corporation	18,355	Japan
Paltac Corporation	14,944	Japan

Information related to impairment losses on fixed assets for each reportable segment

FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)

No reportable information.

FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)

No reportable information.

Information related to goodwill amortization and the unamortized balance by reportable segment

FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)

(Millions of yen)

	Reportable segment					Others	Elimination or corporate	Total
	Japan	America	Europe	Asia	Subtotal			
Amortization Expense	191	54	-	-	246	-	-	246
Unamortized Balance	958	-	-	-	958	-	-	958

FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)

(Millions of yen)

	Reportable segment					Others	Elimination or corporate	Total
	Japan	America	Europe	Asia	Subtotal			
Amortization Expense	191	-	-	0	192	-	-	192
Unamortized Balance	766	-	-	-	766	-	-	766

Information related to negative goodwill profits by reportable segment

FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)

No reportable information.

FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)

No reportable information.

Per-share Information

(Yen)

Item	FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)	FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)
Net assets per share	703.93	789.83
Net income per share	69.60	68.78
Diluted net income per share	69.31	68.49

Notes: 1. Basis for calculation of net income per share and diluted net income per share are as follows.

(Millions of yen)

Item	FY3/12 (Apr. 1, 2011 – Mar. 31, 2012)	FY3/13 (Apr. 1, 2012 – Mar. 31, 2013)
Net income per share		
Net income	8,184	8,087
Amount not available to common stock shareholders	-	-
Net income applicable to common stock	8,184	8,087
Average number of common stock shares outstanding during the period (thousand shares)	117,585	117,590
Diluted net income per share		
Adjusted to net income	-	-
Increase in the number of common stock shares (thousand shares)	499	495
[of which stock acquisition rights (thousand shares)]	[499]	[495]
Summary of dilutive shares not included in the calculation of “diluted net income per share” since there was no dilutive effect.		-

2. Basis for calculation of net assets per share is as follows.

(Millions of yen)

Item	FY3/12 (As of Mar. 31, 2012)	FY3/13 (As of Mar. 31, 2013)
Total net assets on the balance sheets	83,627	93,771
Deduction on total net assets		
[of which stock acquisition rights]	579	573
[of which minority interests]	273	320
Net assets applicable to common stock	82,773	92,876
Number of common stock shares used in calculation of net assets per share (thousand shares)	117,588	117,591

Material Subsequent Events

No reportable information.

** This financial report is solely a translation of “Kessan Tanshin” (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.*